Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.

Trial Details

NCT ID
NCT07283835
Phase
PHASE2
Sponsor
Lepu Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Cretostimogene Grenadenorepvec
  • n-dodecyl-B-D-maltoside
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Wuhan, Hubei, China|30.58333,114.26667
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • In order to be eligible for participation in this trial, the patient must:
  • Be ≥18 years of age on day of signing informed consent.
  • \- Patients must have pathologically confirmed BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or wi…
  • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →